AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6225405 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatment
Number of subjects: 0
Study 6225405 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine hydrochloride
Number of subjects: 0
Study 6225405 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 0
Study 6225405 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine and Clorgyline (combined case)
Number of subjects: 0
Study 31419229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 2102
Study 31419229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 27321067 — intervention group
Group type: EXPERIMENTAL
Intervention: Client‐centred activity of daily living intervention (CADL)
Number of subjects: 33
Study 27196493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial intraosseous access using NIO device
Number of subjects: 42
Study 27196493 — intervention group
Group type: COMPARATOR
Intervention: Humeral intraosseous access using NIO device
Number of subjects: 42
Study 24189504 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Late Stent Thrombosis (VLST)
Number of subjects: 152
Study 24189504 — intervention group
Group type: COMPARATOR
Intervention: Early Stent Thrombosis (EST)
Number of subjects: 152
Study 24189504 — intervention group
Group type: COMPARATOR
Intervention: Late Stent Thrombosis (LST)
Number of subjects: 152
Study 24189504 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 152
Study 24189504 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS)
Number of subjects: 152
Study 22595038 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil (5 mg q.d)
Number of subjects: 18
Study 22595038 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 20933082 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract for 21 days
Number of subjects: 0
Study 17428104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral satraplatin plus prednisone
Number of subjects: 600
Study 17428104 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent satraplatin
Number of subjects: 600
Study 17428104 — intervention group
Group type: EXPERIMENTAL
Intervention: Satraplatin
Number of subjects: 600
Study 15632662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (DOB)
Number of subjects: 20
Study 15632662 — intervention group
Group type: COMPARATOR
Intervention: Exercise echocardiography (EX)
Number of subjects: 20
Study 12806756 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM group
Number of subjects: 32
Study 12806756 — intervention group
Group type: COMPARATOR
Intervention: No TEAM group
Number of subjects: 32
Study 12806756 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-course questionnaire
Number of subjects: 32
Study 10477983 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐512 (Fuji III LC)
Number of subjects: 14
Study 10477983 — intervention group
Group type: COMPARATOR
Intervention: Delton Opaque
Number of subjects: 14
Study 8943507 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg vaginal progesterone per day)
Number of subjects: 283
Study 8943507 — intervention group
Group type: COMPARATOR
Intervention: Utrogestan (300 mg oral micronized progesterone)
Number of subjects: 283
Study 1647293 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.5-1.0 mg, i.m.) administered at 6, 30 and 54 h after methadone pre-treatment
Number of subjects: 6
Study 1647293 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.5-1.0 mg, i.m.) administered only at 54 h after methadone pre-treatment
Number of subjects: 6
Study 6190441 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex
Number of subjects: 58
Study 6190441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 6190441 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex and Placebo
Number of subjects: 58
Study 31974589 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 34
Study 31974589 — intervention group
Group type: COMPARATOR
Intervention: No haemodialysis (Control)
Number of subjects: 34
Study 29717621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using The Internet
Number of subjects: 1149
Study 29717621 — intervention group
Group type: COMPARATOR
Intervention: HealthWatch
Number of subjects: 1149
Study 26614250 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO) exposure from woodsmoke, measured with 72 hour personal monitoring at study enrollment.
Number of subjects: 817
Study 24552155 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 15 mg weekly
Number of subjects: 215
Study 24552155 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Number of subjects: 215
Study 24552155 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg biweekly
Number of subjects: 215
Study 24552155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 24204044 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment
Number of subjects: 0
Study 19995366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional vincristine (0.3-0.8 mm injected in a single nodule)
Number of subjects: 151
Study 19995366 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar lesion kept under clinical observation)
Number of subjects: 151
Study 18214667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost diary for families with an anxious child
Number of subjects: 118
Study 18214667 — intervention group
Group type: COMPARATOR
Intervention: Families from the general population
Number of subjects: 118
Study 18214667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up approach for clinically anxious children
Number of subjects: 118
Study 18214667 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical anxiety disorders in childhood
Number of subjects: 118
Study 17684879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 15 microg
Number of subjects: 40
Study 17684879 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 12702897 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (500-2500 mg)
Number of subjects: 17
Study 12702897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11028111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0
Study 11028111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8863693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (up to 0.15 mg/kg body weight)
Number of subjects: 20
Study 8863693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pethidine (up to 1.5 mg/kg body weight)
Number of subjects: 20
Study 1323160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate combined with oral verapamil
Number of subjects: 40
Study 1323160 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate only
Number of subjects: 40
Study 1323160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine
Number of subjects: 40
Study 6344283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (1 gram intravenously at the time of cord clamping and again four and eight hours later)
Number of subjects: 100
Study 6344283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29097438 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain diet
Number of subjects: 60
Study 29097438 — intervention group
Group type: COMPARATOR
Intervention: Refined grain diet
Number of subjects: 60
Study 30998881 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment aid (printed copy of GCS scoring table)
Number of subjects: 32
Study 30998881 — intervention group
Group type: COMPARATOR
Intervention: No assessment aid (control group)
Number of subjects: 32
Study 30998881 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment aid
Number of subjects: 32
Study 27306347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, amoxicillin, and omeprazole (CAO)
Number of subjects: 66
Study 27306347 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, furazolidone, and omeprazole (FAO)
Number of subjects: 66
Study 24401159 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BoNT‐A)
Number of subjects: 0
Study 24401159 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study 23027721 — intervention group
Group type: EXPERIMENTAL
Intervention: stationary cycling to music
Number of subjects: 30
Study 23027721 — intervention group
Group type: COMPARATOR
Intervention: interactive video game cycling
Number of subjects: 30
Study 19679057 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 testing
Number of subjects: 1364
Study 19679057 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 testing with ER status information
Number of subjects: 1364
Study 19679057 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 testing with tumor grade information
Number of subjects: 1364
Study 19679057 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 testing with tumor size information
Number of subjects: 1364
Study 19679057 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 testing with lymph node status information
Number of subjects: 1364
Study 17356388 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) > or =90 mg/L
Number of subjects: 76
Study 17356388 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 76
Study 17356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemotactic protein-1 (MCP-1)
Number of subjects: 76
Study 17356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8 (IL-8)
Number of subjects: 76
Study 17356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 or 3 markers (CRP, MCP-1, IL-8)
Number of subjects: 76
Study 17356388 — intervention group
Group type: COMPARATOR
Intervention: CRP, IL-8, and MCP-1 levels
Number of subjects: 76
Study 15712717 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized filtering technique for heart rate variability analysis
Number of subjects: 0
Study 15712717 — intervention group
Group type: COMPARATOR
Intervention: Fast Fourier Transformation (FFT)
Number of subjects: 0
Study 11282797 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum vitamin B(6) levels
Number of subjects: 300
Study 11282797 — intervention group
Group type: COMPARATOR
Intervention: Serum folate
Number of subjects: 300
Study 11282797 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B(12)
Number of subjects: 300
Study 11282797 — intervention group
Group type: COMPARATOR
Intervention: Homocysteine
Number of subjects: 300
Study 9924560 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-free metered dose inhaler (Airomir®)
Number of subjects: 201
Study 9924560 — intervention group
Group type: COMPARATOR
Intervention: Current inhaler (CFC-containing)
Number of subjects: 201
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.25 g/m2 for 28 days
Number of subjects: 111
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/m2 for 28 days
Number of subjects: 111
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.75 g/m2 for 28 days
Number of subjects: 111
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 1.0 g/m2 for 28 days
Number of subjects: 111
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 1.5 g/m2 for 28 days
Number of subjects: 111
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 2.0 g/m2 for 28 days
Number of subjects: 111
Study 8028034 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 3.0 g/m2 for 28 days
Number of subjects: 111
Study 2659383 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 200 mg x 3 daily for patients <30 kg or 400 mg x 2 daily for patients >30 kg
Number of subjects: 52
Study 2659383 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 52
Study 2659383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1093604 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cephaloridine
Number of subjects: 192
Study 1093604 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine spray
Number of subjects: 192
Study 30611913 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 131
Study 30611913 — intervention group
Group type: COMPARATOR
Intervention: OPE
Number of subjects: 131
Study 28002684 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 23
Study 28002684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat flour)
Number of subjects: 23
Study 25218817 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic knee strength measures
Number of subjects: 82
Study 25218817 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric isokinetic measures
Number of subjects: 82
Study 23706654 — intervention group
Group type: EXPERIMENTAL
Intervention: GSV surgery with high ligation of the SFJ (group A, n = 60)
Number of subjects: 120
Study 23706654 — intervention group
Group type: COMPARATOR
Intervention: GSV surgery without high ligation of the SFJ (group B, n = 60)
Number of subjects: 120
Study 21127475 — intervention group
Group type: EXPERIMENTAL
Intervention: α-cyclodextrin (α-CD)
Number of subjects: 41
Study 21127475 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 41
Study 19168019 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lyophilisate (Minirinmelt)
Number of subjects: 214
Study 19168019 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin tablets (0.2 or 0.4 mg)
Number of subjects: 214
Study 19168019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (lyophilisate and tablet)
Number of subjects: 214
Study 17360873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (200 mg base/day for 3 days, followed by 200 mg/week for 8 weeks)
Number of subjects: 27
Study 17360873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with 8 weeks of tafenoquine
Number of subjects: 27
Study 17360873 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine with primaquine (22.5 mg/day for 14 days)
Number of subjects: 27
Study 15205859 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 23
Study 11474382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflex stent
Number of subjects: 100
Study 11474382 — intervention group
Group type: EXPERIMENTAL
Intervention: Flamingo Wallstent
Number of subjects: 100
Study 11474382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gianturco‐Z stent
Number of subjects: 100
Study 11474382 — intervention group
Group type: COMPARATOR
Intervention: All stents
Number of subjects: 100
Study 9510582 — intervention group
Group type: EXPERIMENTAL
Intervention: geG 0.5 mg
Number of subjects: 264
Study 9510582 — intervention group
Group type: EXPERIMENTAL
Intervention: geG 0.25 mg
Number of subjects: 264
Study 9510582 — intervention group
Group type: COMPARATOR
Intervention: HBB 20 mg
Number of subjects: 264
Study 7857751 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor (enalapril) added to conventional heart failure therapy
Number of subjects: 0
Study 7857751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydralazine and nitrates in addition to conventional treatment
Number of subjects: 0
Study 3053605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 0
Study 3053605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28676100 — intervention group
Group type: EXPERIMENTAL
Intervention: G-BM
Number of subjects: 101
Study 28676100 — intervention group
Group type: COMPARATOR
Intervention: G-PBSC
Number of subjects: 101
Study 25055078 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (12 weeks of exercise training and 1 year of psychoeducational follow-up)
Number of subjects: 196
Study 25055078 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study 23258423 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw mother's own milk
Number of subjects: 303
Study 23258423 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized mother's own milk
Number of subjects: 303
Study 21497631 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 or 30 μg of inactivated influenza vaccine, followed by a 15 μg booster vaccine
Number of subjects: 731
Study 18271716 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot procedure
Number of subjects: 31
Study 18271716 — intervention group
Group type: COMPARATOR
Intervention: Telescopic procedure
Number of subjects: 31
Study 17315706 — intervention group
Group type: EXPERIMENTAL
Intervention: Levitra (vardenafil; 5 mg per os each other day)
Number of subjects: 60
Study 17315706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Levitra)
Number of subjects: 60
Study 14520773 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (SynchroSonic)
Number of subjects: 70
Study 14520773 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 70
Study 12036804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched preterm formula
Number of subjects: 197
Study 12036804 — intervention group
Group type: COMPARATOR
Intervention: Standard formula or banked breast milk
Number of subjects: 197
Study 12036804 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk intake
Number of subjects: 197
Study 9848041 — intervention group
Group type: EXPERIMENTAL
Intervention: Limulus amebocyte lysate (LAL) assay using QCL‐1000 kit
Number of subjects: 45
Study 9848041 — intervention group
Group type: EXPERIMENTAL
Intervention: Limulus amebocyte lysate (LAL) assay
Number of subjects: 45
Study 9848041 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with concomitant fungal infections
Number of subjects: 45
Study 9848041 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated LAL
Number of subjects: 45
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal complaints (pain at various sites)
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper back pain
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle/foot pain
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder pain
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nonsteroidal antiinflammatory drugs
Number of subjects: 0
Study 7837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain limiting activities
Number of subjects: 0
Study 2764545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg
Number of subjects: 16
Study 2764545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1,000 mg
Number of subjects: 16
Study 2764545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1,500 mg
Number of subjects: 16
Study 2764545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2,000 mg
Number of subjects: 16
Study 360245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 27
Study 360245 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 27
Study 30565981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (short) - played 3 hours during the last week of the 6-week intervention period
Number of subjects: 52
Study 30565981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (long) - played 18 hours over 6 weeks
Number of subjects: 52
Study 28319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity without treatment rationale
Number of subjects: 286
Study 28319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity with treatment rationale
Number of subjects: 286
Study 28319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation without treatment rationale
Number of subjects: 286
Study 28319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation with treatment rationale
Number of subjects: 286
Study 28319696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 286
Study 25283362 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone anchored PEEK cage (PREVAIL)
Number of subjects: 50
Study 25283362 — intervention group
Group type: COMPARATOR
Intervention: PEEK cage with plating
Number of subjects: 50
Study 23475289 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone 70 mg/day for 12 weeks
Number of subjects: 85
Study 23475289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: Solid gelatin (6g)
Number of subjects: 43
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: Liquid gelatin (6g)
Number of subjects: 43
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (75g)
Number of subjects: 43
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: G50:F50 mixture (75g)
Number of subjects: 43
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: Solid whey protein (50g)
Number of subjects: 43
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: Liquid whey protein (50g)
Number of subjects: 43
Study 20733582 — intervention group
Group type: COMPARATOR
Intervention: Control (water for experiments 1 and 3, calorie-free sweetened water for experiment 2)
Number of subjects: 43
Study 18768245 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (360mg daily)
Number of subjects: 38
Study 18768245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16522911 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized dispersible ferric pyrophosphate (MDFP) in wheat-based meal
Number of subjects: 26
Study 16522911 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate in wheat-based meal
Number of subjects: 26